These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6442131)

  • 21. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Use of polyvalent vaccine against Pseudomonas aeruginosa in extensive burns].
    Nasiłowski W; Zietkiewicz W; Brudzyńska-Charewicz S; Bukowska D; Serafińska D; Rudowski W
    Pol Tyg Lek; 1981 Aug; 36(32):1207-11. PubMed ID: 6798556
    [No Abstract]   [Full Text] [Related]  

  • 23. Assessment of the effectiveness of antipseudomonas biological management in the control of infection in burn patients.
    Gonzáles Ayala SE; Daroda M; Villa J; Cecchini E; Vich J
    Panminerva Med; 1983; 25(3):203-8. PubMed ID: 6422426
    [No Abstract]   [Full Text] [Related]  

  • 24. Changes in pools of autoantibodies and anti-bacterial antibodies in patients suffering from recurrent infections of the urinary tract and undergoing bacterial immunization treatment.
    Stojanović M; Inić-Kanada A; Popović Z; Zivković I; Dimitrijević L
    Immunol Lett; 2004 Jun; 94(1-2):123-33. PubMed ID: 15234544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pseudomonas vaccination and immunotherapy: an overview.
    Holder IA
    J Burn Care Rehabil; 2001; 22(5):311-20. PubMed ID: 11570530
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of carbenicillin, gentamicin and vaccines on rats experimentally burned and infected with Pseudomonas aeruginosa.
    Toama MA; Hamed IM; Ashour SM
    Pharmazie; 1980; 35(4):228-30. PubMed ID: 6773076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease.
    Sorichter S; Baumann U; Baumgart A; Walterspacher S; von Specht BU
    Vaccine; 2009 May; 27(21):2755-9. PubMed ID: 19366571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis.
    Bauernfeind A; Przyklenk B
    Behring Inst Mitt; 1997 Feb; (98):256-61. PubMed ID: 9382748
    [No Abstract]   [Full Text] [Related]  

  • 29. [Role of immunotherapy in the treatment of suppurative mediastinitis].
    Abakumov MM; Pogodina AN; Grigor'ev NI; Titova TI; Sidorova TN
    Vestn Khir Im I I Grek; 1984 Mar; 132(3):13-6. PubMed ID: 6426117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
    Joó I; Stanislavskii ES
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical use of monovalent vaccines in the treatment of Pseudomonas aeruginosa infection.
    De Fajardo CL; Delfino AH; Laborde HF
    Prog Immunobiol Stand; 1971; 5():425-7. PubMed ID: 4633970
    [No Abstract]   [Full Text] [Related]  

  • 32. Vaccinations against Pseudomonas aeruginosa: active and passive alternatives.
    Bellanti JA; Zeligs BJ; Kulczycki LL
    Pediatr Pulmonol Suppl; 1997; 16():269-70. PubMed ID: 9443307
    [No Abstract]   [Full Text] [Related]  

  • 33. [Complex treatment of pyocyanosis (review of the literature)].
    Rozhavin MA; Sologub VV
    Vrach Delo; 1981 Mar; (3):4-8. PubMed ID: 6794225
    [No Abstract]   [Full Text] [Related]  

  • 34. Complicated urinary tract infection caused by Pseudomonas aeruginosa in a single institution (1999-2003).
    Shigemura K; Arakawa S; Sakai Y; Kinoshita S; Tanaka K; Fujisawa M
    Int J Urol; 2006 May; 13(5):538-42. PubMed ID: 16771722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunologic prevention and treatment of wound infection in open fractures and osteomyelitis].
    Bialik IF; Burdyga FA; Grigor'ev NI; Krokhina MA; Kalashnik AF
    Ortop Travmatol Protez; 1981 Aug; (8):17-21. PubMed ID: 6793953
    [No Abstract]   [Full Text] [Related]  

  • 36. [Use of Sanoserum P.A. in the treatment of Pseudomonas aeruginosa infection].
    Philips R; Philips I
    Klin Oczna; 1987 Apr; 89(4):158-9. PubMed ID: 3118093
    [No Abstract]   [Full Text] [Related]  

  • 37. Pseudomonas immunoglobulin and vaccine in burn patients.
    Bose B
    Lancet; 1981 Feb; 1(8217):435. PubMed ID: 6110056
    [No Abstract]   [Full Text] [Related]  

  • 38. [Serum level of Pseudomonas aeruginosa-specific IgA in patients with chronic lower respiratory tract infection and its clinical significance].
    Tsukada H; Suzuki E; Wada K; Arakawa M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Oct; 31(10):1227-34. PubMed ID: 8271654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Use of kasugamycin in urinary tract infection, especially against Pseudomonas aeruginosa].
    Tada S; Hakamada T; Mori O; Yamazaki Y
    Hinyokika Kiyo; 1968 Jan; 14(1):50-6. PubMed ID: 4971183
    [No Abstract]   [Full Text] [Related]  

  • 40. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.